| Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B |
| Yuen Man-Fung1, Berliba Elina2, Sukeepaisarnjaroen Wattana3, Ahn Sang Hoon4, Tanwandee Tawesak5, Lim Young-Suk6, Kim Yoon Jun7, Poovorawan Kittiyod5, Tangkijvanich Pisit8, Schwabe Christian9, Eley Timothy10, Brown Joanne10, Noi Autori1, Gane Edward John11 |
1 University of Hong Kong, Hong Kong,
4 Yonsei University, Seoul,
5 Mahidol University, Bangkok,
6 Asan Medical Center, Seoul,
7 Seoul National University,
9 Auckland Clinical Studies, Auckland,
10 Arbutus Biopharma, Warminster,
11 University of Auckland |
| Hepatology Communications |
| Nr. / 2022 / ISSN 2471-254X |
| Disponibil online 12 September, 2023. Descarcări-4. Vizualizări-190 |
----------------------------------------------------------------------------------------------------------------------------------- | Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection |
| Bazinet Michel1, Pântea Victor2, Cebotarescu Valentin2, Cojuhari Lilia2, Jimbei Paulina3, Anderson Mark4, Gersch Jeffrey4, Holzmayer Vera4, Elsner Carina5, Krawczyk Adalbert5, Kuhns Mary C.4, Cloherty Gavin A.4, Dittmer Ulf5, Vaillant Andrew1 |
2 ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
3 Toma Ciorba Clinical Hospital of Infectious Diseases,
4 Abbott Diagnostics, Abbott Park, IL,
5 Duisburg - Essen University |
| Hepatology Communications |
| Nr. / 2021 / ISSN 2471-254X |
| Disponibil online 13 September, 2021. Descarcări-2. Vizualizări-311 |
----------------------------------------------------------------------------------------------------------------------------------- | Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial |
| Bazinet Michel1, Pântea Victor2, Cebotarescu Valentin2, Cojuhari Lilia2, Jimbei Paulina3, Albrecht Jeff A4, Schmid Peter4, Le Gal Frederic5, Gordien Emmanuel5, Krawczyk Adalbert6, Mijocevic Hrvoje7, Karimzadeh Hadi7, Roggendorf Michael7, Vaillant Andrew1 |
2 ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
3 Toma Ciorba Clinical Hospital of Infectious Diseases,
6 Duisburg - Essen University,
|
| The Lancet Gastroenterology and Hepatology |
| Nr. / 2017 / ISSN 2468-1253 |
| Disponibil online 11 December, 2017. Descarcări-1. Vizualizări-798 |
-----------------------------------------------------------------------------------------------------------------------------------
1-3 of 3
